NASDAQ · MOVE
Corvex, Inc.
$7.22-$0.09 (-1.23%)
Corvex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.29% below the high.
Loading market information…
NASDAQ · NAOV · USD
Stock price, earnings
Quote as of Mar 11, 2026, 01:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
NanoVibronix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.83% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow NanoVibronix, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
NanoVibronix, Inc., operating through its subsidiary NanoVibronix Ltd., develops and commercializes innovative, non-invasive devices that stimulate biological responses for therapeutic purposes. Their core focus areas include mitigating biofilm formation, accelerating wound repair, and alleviating pain. Key among their product line is UroShield, an ultrasound-based solution engineered to deter bacterial colonization and biofilm development in urinary catheters, thereby boosting antibiotic efficacy and reducing associated patient discomfort. They also offer PainShield and WoundShield, both patch-based therapeutic ultrasound technologies. PainShield targets relief from pain, muscle spasms, and joint contractures, while WoundShield is designed to foster tissue regeneration and promote healing in wounds. The company distributes these products directly to consumers and via extensive distributor networks spanning the United States, Israel, Europe, India, and numerous other international regions. Founded in 2003, NanoVibronix, Inc. maintains its corporate headquarters in Elmsford, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.22-$0.09 (-1.23%)
Corvex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.29% below the high.
$3.61+$0.24 (+7.12%)
HeartSciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.2% below the high.
$4.88+$0.14 (+2.95%)
ENDRA Life Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.78% below the high.
$4.77+$0.26 (+5.76%)
CNS Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.74% below the high.
$1.97-$0.07 (-3.43%)
Aclarion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.95% below the high.
$1.57-$0.06 (-3.38%)
GRI Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.55% below the high.
$0.39-$0.00 (-0.94%)
Bone Biologics Corporation’s quoted price sits in the lower half of its reported 52-week range, 83.75% below the high.
$2.04-$0.11 (-5.12%)
Autonomix Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.73% below the high.
